Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trimeris (TRMS) -- Ignore unavailable to you. Want to Upgrade?

To: Elroy Jetson who wrote (35)	1/21/1998 5:11:00 PM
From: Pseudo Biologist	Read Replies (1) \| Respond to of 108

Elroy, yes I did. This is the link to the press release biz.yahoo.com I am not sure I would call this "most promising" but it is an interesting approach, and it is complementary at least in principle to the current components of HAART, which currently includes one or more protease inhibitors and two or more reverse transcriptase inhibitors. I doubt T-20, or anything at this point, would work as single therapy for HIV. Many investors/analysts/etc have problems with T-20 being a peptide as opposed to a small molecule, but T-20 is said to have "surprisingly long half life," which helps some. Use of the MiniMed "pump" is also interesting; I understand they use this for insulin, another peptide of roughtly the same size as T-20. It's early to tell, to say the least. PB